The faculty and staff of Scott & White, Olin E. Teague Veteran's Center and Texas A&M University College of Medicine are committed to clinical and basic oncology research as part of a program of excellence in cancer care. Participation in the Southwest Oncology Group (SWOG) is a critical part of our clinical research program. Our two hospitals and associated clinics are the main teaching facilities for the Texas A&M University College of Medicine and the clinical campus is co-located at Scott & White and the VA facilities. Scott & White Hospital has 309 active beds and, in the associated clinic, 750,000 outpatients are seen per year. The Olin E. Teague VA Hospital has 510 active beds. In both hospitals there are over 2,000 new cancer patients seen per year. Our group has participated as a member institution since the inception of SWOG. Since the last granting period our program has been expanded and enhanced. The number of medical, radiation, and surgical oncologists have increased since the last year granting period: e.g., there are five new members of the Medical Oncology Division, 2 new members of Radiation Oncology and there are now 50 members of SWOG. Multi-modality therapy and collaboration in clinical research are enhanced by joint clinics, and multidisciplinary patient care conferences. Since last granting period, there have been many new initiatives in clinical research including programs in developmental biologics, breast cancer, and head and neck cancer. Our institutions have concomitantly, with development of these programs, increased our scientific contributions to SWOG and our patient accrual (e.g., we have submitted over 10 proposed studies, have three active SWOG protocols authored by our physicians and have accrued 140 patients in the last calendar year--double the number of previous years). Data management and accrual have been greatly improved by streamlined administrative procedures, hiring of a nurse clinician and third data manager and continued use of our computer-patient management system, OPRA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA028862-13
Application #
3557005
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1997-12-31
Budget Start
1993-02-25
Budget End
1993-12-31
Support Year
13
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Scott and White Memorial Hospital
Department
Type
DUNS #
076697960
City
Temple
State
TX
Country
United States
Zip Code
76504
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Chu, David Z J; Hussey, Michael A; Alberts, David S et al. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 10:310-6
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Dhodapkar, Madhav V; Hoering, Antje; Gertz, Morie A et al. (2009) Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113:793-6
Swinnen, Lode J; Rankin, Cathryn; Carraway, Hetty et al. (2008) A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol 86:353-8

Showing the most recent 10 out of 40 publications